Blue Earth Diagnostics Overview
- Founded
- 2014

- Status
- Private
- Employees
- 100

- Latest Deal Type
- M&A
- Latest Deal Amount
- $466M

Blue Earth Diagnostics General Information
Description
Developer of molecular imaging agents designed to address unmet clinical needs and reliably inform diagnosis decisions. The company imaging agents can be used for PET imaging to detect and localize prostate cancer in men with the diagnosis of biochemical recurrence as well as in amino acid transport and radiopharmaceutical therapies, enabling medical practitioners to diagnose and treat brain and prostate cancer patients with improved efficiency.
Contact Information
- The Oxford Science Park
- Magdalen Centre, Robert Robinson Avenue
- Oxford OX4 4GA
- England, United Kingdom
Blue Earth Diagnostics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Merger/Acquisition | 01-Aug-2019 | $466M | 000.00 | 00000 | Completed | Profitable |
1. Early Stage VC | 11-Mar-2014 | 000.00 | 000.00 | Completed | Startup |
Blue Earth Diagnostics Executive Team (15)
Blue Earth Diagnostics Board Members (4)
Name | Representing | Role | Since |
---|---|---|---|
Elisa Petris Ph.D | Syncona | Board Member | 000 0000 |
Jonathan Allis Ph.D | Blue Earth Diagnostics | Co-Founder, Board Member & Chief Executive Officer | 000 0000 |
Martin Murphy Ph.D | Self | Chairman | 000 0000 |
Blue Earth Diagnostics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial